Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

127.73 +8.95 (+7.53%)
Official Closing Price Updated: 4:10 PM EDT, Mar 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 18,467,908
Open 122.88
Bid (Size) 127.50 (200)
Ask (Size) 127.65 (300)
Prev. Close 118.78
Today's Range 122.74 - 127.95
52wk Range 66.66 - 132.09
Shares Outstanding 541,500
Dividend Yield 1.27%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge
The small-cap segment of the U.S. stock market has officially entered correction territory, marking a stark reversal for a sector that many analysts expected to lead the "Great Rotation" of 2026. On... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but... 
Via The Motley Fool
Topics Derivatives ETFs Regulatory Compliance

Performance

YTD
+5.1%
+5.1%
1 Month
+0.9%
+0.9%
3 Month
+3.5%
+3.5%
6 Month
+28.5%
+28.5%
1 Year
+57.5%
+57.5%

More News

Read More
News headline image
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗
Via Stocktwits
Topics ETFs
News headline image
The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)
Via Finterra
Topics ETFs Intellectual Property
News headline image
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗
Via Stocktwits
Topics ETFs
News headline image
QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗
Via Stocktwits
News headline image
QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗
Via Stocktwits
Topics Initial Public Offering
News headline image
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗
Via Stocktwits
News headline image
IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗
Via Stocktwits
News headline image
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗
Via Stocktwits
News headline image
Why Did CRMD Stock Tumble Over 11% Today? ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗
Via Stocktwits
Topics Economy
News headline image
IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Why Did QURE Stock Almost Halve Pre-Market Today? ↗
Via Stocktwits
News headline image
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗
Via Stocktwits
News headline image
IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗
Via Stocktwits
News headline image
CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗
Via Stocktwits
Topics Earnings
News headline image
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts ↗
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
Why Did PVLA Stock Surge 45% In Pre-Market Today? ↗
Via Stocktwits
News headline image
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder ↗
Via Stocktwits
News headline image
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts ↗
Via Stocktwits

Frequently Asked Questions

Is State Street SPDR S&P Biotech ETF publicly traded?
Yes, State Street SPDR S&P Biotech ETF is publicly traded.
What exchange does State Street SPDR S&P Biotech ETF trade on?
State Street SPDR S&P Biotech ETF trades on the New York Stock Exchange
What is the ticker symbol for State Street SPDR S&P Biotech ETF?
The ticker symbol for State Street SPDR S&P Biotech ETF is XBI on the New York Stock Exchange
What is the current price of State Street SPDR S&P Biotech ETF?
The current price of State Street SPDR S&P Biotech ETF is 127.73
When was State Street SPDR S&P Biotech ETF last traded?
The last trade of State Street SPDR S&P Biotech ETF was at 03/31/26 04:10 PM ET
What is the market capitalization of State Street SPDR S&P Biotech ETF?
The market capitalization of State Street SPDR S&P Biotech ETF is 69.17M
How many shares of State Street SPDR S&P Biotech ETF are outstanding?
State Street SPDR S&P Biotech ETF has 69M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.